Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 7 | Journal of Translational Medicine

Fig. 7

From: Molecule interacting with CasL-2 enhances tumor progression and alters radiosensitivity in cervical cancer

Fig. 7

Patients with cervical cancer having high MICAL2 expression exhibited poor clinical response to radiotherapy. A Among the 62 patients with cervical cancer who underwent radiotherapy, 38 patients achieved a complete response (CR), 17 patients had a partial response (PR), and 7 patients either had stable disease (SD) or experienced disease progression (PD) six months post-radiotherapy. B MICAL2 expression levels in cervical cancer tissues from 2 cases with CR and 1 case with SD, along with their corresponding MRI images (transverse and median sagittal sections) taken before and after radiotherapy. C Kaplan–Meier survival analysis with log-rank test used to assess disease-free progression (DFS) in patients with cervical cancer based on different MICAL2 expression levels (n = 62)

Back to article page